[{"address1": "1000 Skokie Boulevard", "address2": "Suite 350", "city": "Wilmette", "state": "IL", "zip": "60091", "country": "United States", "phone": "847 388 0349", "website": "https://www.monopartx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.", "fullTimeEmployees": 9, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher M. Starr Ph.D.", "age": 71, "title": "Co-Founder & Independent Executive Chairman of the Board", "yearBorn": 1952, "fiscalYear": 2023, "totalPay": 200000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc", "age": 39, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1984, "fiscalYear": 2023, "totalPay": 710500, "exercisedValue": 0, "unexercisedValue": 56986}, {"maxAge": 1, "name": "Mr. Andrew J. Cittadine M.B.A.", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 416700, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Karthik  Radhakrishnan CFA", "age": 52, "title": "CFO, Principal Accounting Officer & Principal Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Patrice P. Rioux M.D., Ph.D.", "age": 72, "title": "Acting Chief Medical Officer", "yearBorn": 1951, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 24.46, "open": 26.0, "dayLow": 24.3023, "dayHigh": 26.0, "regularMarketPreviousClose": 24.46, "regularMarketOpen": 26.0, "regularMarketDayLow": 24.3023, "regularMarketDayHigh": 26.0, "beta": 1.104, "forwardPE": -9.554032, "volume": 38506, "regularMarketVolume": 38506, "averageVolume": 541896, "averageVolume10days": 46580, "averageDailyVolume10Day": 46580, "bid": 24.34, "ask": 26.47, "bidSize": 100, "askSize": 100, "marketCap": 154596224, "fiftyTwoWeekLow": 1.545, "fiftyTwoWeekHigh": 38.5, "fiftyDayAverage": 21.106, "twoHundredDayAverage": 8.21135, "currency": "USD", "enterpriseValue": 48256572, "floatShares": 1617080, "sharesOutstanding": 6098470, "sharesShort": 49852, "sharesShortPriorMonth": 652492, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.014199999, "heldPercentInsiders": 0.42938, "heldPercentInstitutions": 0.24474001, "shortRatio": 0.15, "shortPercentOfFloat": 0.1022, "impliedSharesOutstanding": 6098470, "bookValue": 1.875, "priceToBook": 13.52, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -7124184, "trailingEps": -1.98, "forwardEps": -2.36, "lastSplitFactor": "1:5", "lastSplitDate": 1723507200, "52WeekChange": 10.816425, "SandP52WeekChange": 0.24176979, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "MNPR", "underlyingSymbol": "MNPR", "shortName": "Monopar Therapeutics Inc.", "longName": "Monopar Therapeutics Inc.", "firstTradeDateEpochUtc": 1576765800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "4c85e6c0-debc-355c-95b2-bf3324d36ecc", "messageBoardId": "finmb_304391755", "gmtOffSetMilliseconds": -18000000, "currentPrice": 25.35, "targetHighPrice": 72.0, "targetLowPrice": 22.0, "targetMeanPrice": 42.0, "targetMedianPrice": 37.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 7118771, "totalCashPerShare": 2.022, "quickRatio": 6.534, "currentRatio": 6.59, "returnOnAssets": -0.53445, "returnOnEquity": -1.02307, "freeCashflow": -4433461, "operatingCashflow": -6817933, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-11"}]